Locoregional Failure During and After Short-course Radiotherapy Followed by Chemotherapy and Surgery Compared With Long-course Chemoradiotherapy and Surgery

Autores de INCLIVA

• 

  Andrés Cervantes Ruiperez

  Autor

Participantes ajenos a INCLIVA

• Dijkstra, Esmee A
• Nilsson, Per J
• Hospers, Geke A P
• Bahadoer, Renu R
• Meershoek-Klein Kranenbarg, Elma
• Roodvoets, Annet G H
• Putter, Hein
• Berglund, Ake
• Crolla, Rogier M P H
• Hendriks, Mathijs P
• Capdevila, Jaume
• Edhemovic, Ibrahim
• Marijnen, Corrie A M
• van de Velde, Cornelis J H
• Glimelius, Bengt
• van Etten, Boudewijn
• and collaborative investigators

Grupos y Plataformas de I+D+i

• Grupo de Investigación en Cáncer Colorrectal y Nuevos Desarrollos Terapéuticos en Tumores Sólidos

  

  Leading Researcher

  Andrés Cervantes Ruiperez

Abstract

Objective:To analyze risk and patterns of locoregional failure (LRF) in patients of the RAPIDO trial at 5 years.Background:Multimodality treatment improves local control in rectal cancer. Total neoadjuvant treatment (TNT) aims to improve systemic control while local control is maintained. At 3 years, LRF rate was comparable between TNT and chemoradiotherapy in the RAPIDO trial.Methods:A total of 920 patients were randomized between an experimental (EXP, short-course radiotherapy, chemotherapy, and surgery) and a standard-care group (STD, chemoradiotherapy, surgery, and optional postoperative chemotherapy). LRFs, including early LRF (no resection except for organ preservation/R2 resection) and locoregional recurrence (LRR) after an R0/R1 resection, were analyzed.Results:Totally, 460 EXP and 446 STD patients were eligible. At 5.6 years (median follow-up), LRF was detected in 54/460 (12%) and 36/446 (8%) patients in the EXP and STD groups, respectively (P=0.07), in which EXP patients were more often treated with 3-dimensional-conformed radiotherapy (P=0.029). In the EXP group, LRR was detected more often [44/431 (10%) vs. 26/428 (6%); P=0.027], with more often a breached mesorectum (9/44 (21%) vs. 1/26 (4); P=0.048). The EXP treatment, enlarged lateral lymph nodes, positive circumferential resection margin, tumor deposits, and node positivity at pathology were the significant predictors for developing LRR. Location of the LRRs was similar between groups. Overall survival after LRF was comparable [hazard ratio: 0.76 (95% CI, 0.46-1.26); P=0.29].Conclusions:The EXP treatment was associated with an increased risk of LRR, whereas the reduction in disease-related treatment failure and distant metastases remained after 5 years. Further refinement of the TNT in rectal cancer is mandated.

Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.

Keywords

• locally advanced rectal cancer; locoregional failure; locoregional recurrence; total neoadjuvant treatment